Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Increasing Flu Vaccination Through Evidence-Based Nudges (INFLUENCE)

10 novembre 2026 mis à jour par: Elena Azzolini, Istituto Clinico Humanitas

Nudge-based Strategies to Increase Influenza Vaccination Uptake Among Health and Social Care Personnel: a Multicentre Cluster-randomised Trial

This study aims to find out whether changing the wording and content of workplace emails can encourage more healthcare and non-healthcare staff to get a seasonal flu vaccine. The main question is whether emails that highlight the benefits of vaccination, the possible consequences of not getting vaccinated, or vaccination rates among colleagues are more effective than standard information emails.

The study will take place during the 2026-2027 flu vaccination campaign across 17 healthcare and social care organizations in Lombardy, Italy. Approximately 45,000 eligible workers are expected to be included, covering both staff who provide patient care and those in administrative, technical, and support roles.

Workplace groups, such as departments or organizational units, are randomly assigned to one of four email communication approaches:

  • Standard information (control): emails communicating that the vaccination campaign is ongoing and that it is possible to get vaccinated.
  • Benefits of vaccination (gain framing): emails emphasizing the potential benefits of vaccination for workers, patients, colleagues, and the organization.
  • Consequences of not getting vaccinated (loss framing): emails emphasizing the possible risks and negative consequences for workers, patients, colleagues, and the organization.
  • Vaccination among colleagues (social norms): emails and follow-up updates showing vaccination progress and, where possible, comparing vaccination rates in the recipient's workplace group with those in other groups.

Researchers will use existing vaccination and employment records to compare the percentage of workers who receive a flu vaccine in each group by the end of the campaign. They will also examine whether the emails encourage earlier vaccination and whether their effects differ across workplaces and staff groups. Where suitable records are available, they will explore differences in sickness absence during the campaign.

Vaccination will remain voluntary, and all workers will continue to have access to the usual vaccination services. The study involves workplace emails and the use of existing records; no additional medical visits, tests, or procedures are required.

The findings will help healthcare organizations decide whether simple changes to routine communication can improve staff flu vaccination rates and which approach works best.

Aperçu de l'étude

Description détaillée

Seasonal influenza represents a major public health issue, associated with morbidity, mortality, pressure on healthcare services, workforce absenteeism and risk of transmission in care settings. Influenza vaccination of healthcare and non-healthcare workers employed in healthcare and social care organisations is an important preventive measure, not only for individual protection, but also for the indirect protection of frail patients, reduction of transmission in healthcare settings, preservation of continuity of care and resilience of healthcare services. Despite the availability of influenza vaccination and public health recommendations, vaccination uptake among healthcare and non-healthcare workers remains suboptimal and variable across organisations, professional profiles and organisational units. Communication strategies informed by behavioural science, commonly referred to as "nudges", represent low-cost, scalable organisational interventions that may guide individuals towards preventive behaviours while preserving individual autonomy. The study aims to evaluate the effectiveness of an organisational and behavioural communication strategy with potential impact on prevention, quality of care pathways, workforce resilience and public health.

Primary objective: to evaluate the effectiveness of nudge-based communication strategies, assigned at organisational cluster level, in increasing influenza vaccination uptake among eligible healthcare and non-healthcare workers during the 2026-2027 influenza vaccination campaign compared with standard institutional communication.

Secondary objectives:

  • to compare the relative effectiveness of the different communication arms, including standard communication, gain framing, loss framing and social norms/peer feedback;
  • to assess the change in influenza vaccination uptake during the 2026-2027 campaign compared with the 2025-2026 campaign, where historical data are available; to evaluate time to vaccination;
  • to explore heterogeneity of effect by organisational cluster, healthcare/non-healthcare area and previous vaccination history, where available;
  • to assess sickness absence indicators at cluster level during the vaccination campaign, where such data are available and comparable across participating organisations;
  • to generate evidence to inform future organisational, regional and potentially national vaccination communication and prevention policies.

Primary endpoint:

Influenza vaccination uptake during the 2026-2027 influenza vaccination campaign, defined as the proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period. Documented vaccinations will be considered irrespective of the setting in which they are administered, including vaccinations administered within the participating organisation or through other authorised vaccination pathways, where captured by ARVAX or other applicable regional administrative data sources.

Secondary endpoints:

  • Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign, at cluster level;
  • Time to vaccination, defined as the number of days between delivery of the communication assigned to the cluster and the documented date of influenza vaccination;
  • Sickness absence indicators at cluster level during the vaccination campaign, including number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time, according to data availability and quality.

Population and patient selection criteria: The study population consists of healthcare and non-healthcare workers eligible for influenza vaccination during the 2026-2027 campaign and belonging to organisational clusters included in the study within the 17 participating Lombardy organisations.

In this protocol, the term "patients/subjects" should be understood as "study participants/workers", since the study is not conducted on assisted patients. Inclusion criteria: employment or affiliation with one of the 17 participating organisations; belonging to an included and randomised organisational cluster; eligibility for influenza vaccination according to applicable regional/organisational recommendations; availability in administrative data flows required to define the denominator; and availability of vaccination outcome data through administrative, regional or organisational data sources.

Exclusion criteria: non-eligibility for influenza vaccination; lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment; belonging to clusters that are not classifiable, mappable or randomizable; termination of employment/affiliation before the start of the campaign if not exposed to the possibility of organisational vaccination; or any other administrative condition preventing correct attribution to cluster, study arm or outcome.

Study design: This is a pragmatic, multicentre, four-arm, parallel-group, cluster-randomised, non-pharmacological procedural-organisational interventional study, prospectively implemented during the 2026-2027 influenza vaccination campaign. Randomisation will occur at the level of organisational clusters, defined as organisational units uniformly identified across participating centres according to FLUPER or another consistent organisational classification available within the participating organisations. Clusters will be allocated in a 1:1:1:1 ratio to one of four arms: standard communication, gain framing, loss framing, and social norms/peer feedback. Outcomes and denominators will be assessed using routinely available administrative, regional and organisational data flows, including FLUPER, the regional healthcare workforce administrative flow used to support workforce denominator definition and organisational classification, and ARVAX, the regional vaccination registry/database used to ascertain vaccination uptake; where available, organisational workforce or human resources data flows used to assess cluster-level sickness absence indicators will be used.

Description of the intervention: The intervention consists of institutional e-mail communications sent by the Vaccination Unit or the competent organisational function of each participating organisation, with content differentiated according to the study arm assigned to the cluster.

  • Arm 1 - Standard communication: standard e-mail containing information on the launch of the influenza vaccination campaign, access procedures, vaccination sites, opening hours and booking channels.
  • Arm 2 - Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.
  • Arm 3 - Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.
  • Arm 4 - Social norms / peer feedback: periodic e-mails providing updates on campaign progress and, where feasible, comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters or the overall cluster average.

The comparator is standard/informational communication, corresponding to routine communication on the launch of the vaccination campaign and on access procedures.

Number of participants planned: The overall expected number of participants will be determined based on FLUPER/organisational data flows and other available administrative sources from the 17 participating organisations before final randomisation. All eligible healthcare and non-healthcare workers belonging to the randomised clusters are expected to be included.

Total number planned: approximately 45,000 healthcare and non-healthcare workers across all 17 participating organisations, subject to confirmation based on the final eligible workforce denominator derived from FLUPER and/or organisational administrative data flows before randomisation. Number planned per arm: approximately one quarter of the overall eligible population, depending on the number and size of randomised cluster

Type d'étude

Interventionnel

Inscription (Estimé)

45000

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Bergamo, Italie
        • ATS Bergamo
      • Brescia, Italie
        • ASST Spedali Civili di Brescia
      • Crema, Italie
        • ASST Crema
      • Desenzano del Garda, Italie
        • ASST Garda
      • Garbagnate Milanese, Italie
        • ASST Rhodense
      • Legnano, Italie
        • ASST Ovest Milanese
      • Lodi, Italie
        • ASST Lodi
      • Milan, Italie
        • Istituto Europeo di Oncologia
      • Milan, Italie
        • ASST Fatebenefratelli-Sacco
      • Milan, Italie
        • ASST Santi Paolo e Carlo
      • Paderno Dugnano, Italie
        • Clinica Polispecialistica San Carlo
      • Pavia, Italie
        • ASST Pavia
      • Pavia, Italie
        • ATS Pavia
      • Sondrio, Italie
        • ASST Valtellina e Alto Lario
      • Treviglio, Italie
        • ASST Bergamo Ovest
      • Vimercate, Italie
        • ASST Brianza
    • Lombardy
      • Milan, Lombardy, Italie, 20089
        • Istituto Clinico Humanitas

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion criteria:

  • employment or affiliation with one of the 17 participating organisations;
  • belonging to an included and randomised organisational cluster;
  • availability in administrative data flows required to define the denominator;
  • availability of vaccination outcome data through administrative regional data sources.

Exclusion criteria:

  • lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment;
  • belonging to clusters that are not classifiable, mappable or randomizable.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Control

Standard communication: standard e-mail informing that the vaccination campaing is ongoing and inviting healthcare workers to participate.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Expérimental: Gain Framing

Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications.

Getting vaccinated against flu protects both individual and community health:

  • It reduces the spread of the flu virus, benefiting care recipients, patients, colleagues, and family members.
  • It reduces the risk of complications in people with chronic conditions.
  • It reduces the risk of a heart attack in the seven days following a confirmed flu infection.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Expérimental: Loss framing

Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications.

Not getting vaccinated against flu increases both individual and community risks:

  • It increases the spread of the flu virus, affecting care recipients, patients, colleagues, and family members.
  • It increases the risk of complications in people with chronic conditions.
  • It increases the risk of a heart attack in the seven days following a confirmed flu infection.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Expérimental: Social norms

Social norms: weekly e-mails providing updates on campaign progress and comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters assigned to the same experimental arm.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

To encourage staff vaccination, the Agency will send a brief weekly update on the campaign's progress from now through December. These updates will compare vaccination rates across selected organizational units within the Agency. The units were selected at random and were formed by grouping organizational structures with similar areas of activity.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Influenza vaccination uptake at the end of 2026-2027 campaign.
Délai: Up to 6 months

Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period of the campaign.

Up to 6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Influenza vaccination uptake at mid 2026-2027 campaign.
Délai: Up to 3 months

Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination at mid of the campaign.

Up to 3 months
Change in influenza vaccination uptake between seasons.
Délai: Baseline and 6 months

Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign.

Baseline and 6 months
Time to vaccination.
Délai: Up to 6 months

The number of days between the delivery of the communication assigned to the cluster and the documented date of influenza vaccination.

Up to 6 months
Sickness absence.
Délai: Up to 6 months

Number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time.

Up to 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 octobre 2026

Achèvement primaire (Estimé)

31 mars 2027

Achèvement de l'étude (Estimé)

31 mars 2027

Dates d'inscription aux études

Première soumission

30 octobre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

No IPD data will be collected as part of the study.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner